We are studying whether navepegritide can help improve growth in adolescents aged 12 to under 18 with achondroplasia. This trial will help us understand its effectiveness and safety.
Health conditions and diseases that the clinical trial is designed to study and treat.
Achondroplasia is a genetic disorder that results in abnormal bone growth, leading to short stature and characteristic features. It primarily affects children and adolescents, causing symptoms such as a larger head, shorter limbs, and a prominent forehead.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.